INOVIQ LTD — Major Shareholding Notification 2016

Jun 19, 2016

603 page 1/2 15 July 2001

Form 603

Corporations Act 2001 Section 671B

Notice of initial substantial holder

To Company Name/Scheme BARD1 LIFE SCIENCES LIMITED (formerly Eurogold Limited)

ACN/ARSN 009 070 384

1. Details of substantial holder (1)

Name DR. IRMGARD IRMINGER-FINGER ACN/ARSN (if applicable)

The holder became a substantial holder on 09/06/2016

2. Details of voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:

Class ofsecurities (4)	Numberofsecurities	Person'svotes (5)	Voting power(6)
Ordinary Shares Escrowed for 24 Months	108,252,420	108,252,420	19.61%
Unquoted Performance Shares Escrowed for 24 Months	108,252,420	108,252,420	Do not hold any voting rights

3. Details of relevant interests

The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

Holder of relevant interest	Nature of relevant interest (7)	Class and number of securities
Dr. Irmgard Irminger-Finger	Direct	108,252,420 Ordinary
Dr. Irmgard Irminger-Finger	Direct	108,252,420 Unquoted Performance Shares

4. Details of present registered holders

The persons registered as holders of the securities referred to in paragraph 3 above are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Class and number of securities
Dr. Irmgard Irminger- Finger	Dr. Irmgard Irminger- Finger	Dr. Irmgard Irminger- Finger	108,252,420 Ordinary
Dr. Irmgard-Irminger Finger	Dr. Irmgard Irminger- Finger	Dr Irmgard Irminger- Finger	108,252,420 Unquoted Performance Shares

5. Consideration

The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:

Holder of relevant interest	Date of acquisition	Consideration (9)	Class and number of securities
Dr. Irmgard Irminger- Finger	9 June 2016	Subject to conditions precedent in the Company’s Prospectus shares were issued for payment of 1,299,081 shares in BARD1AG	108,252,420 Ordinary Shares Escrowed for 24 Months 108,252,420 Unquoted Performance Shares Escrowed for 24 Months

6. Associates

The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
Dr. Irmgard Irminger-Finger	Beneficial Holder

7. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Dr Irmgard Irminger-Finger	10 Rue Viollier, Geneva, Switzerland 1207

Signature

print name Dr. Irmgard Irminger-Finger

capacity Beneficial Holder

sign here date 17/06/2016

DIRECTIONS

If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the (1) manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 7 of the form.

• (2) See the definition of "associate" in section 9 of the Corporations Act 2001.

• (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.

• (4) The voting shares of a company constitute one class unless divided into separate classes.

The total number of votes attached to all the voting shares in the company or voting interests in the scheme (if any) that the person or an (5) associate has a relevant interest in.

• (6) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.

• (7) Include details of:

any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection 671B(4) applies, a (a) copy of any document setting out

the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany

this form, together with a written statement certifying this contract, scheme or arrangement; and

any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or (b) disposal of the securities to

which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.

• (8)[If the substantial holder is unable to determine the identity of the person ( eg. if the relevant interest arises because of an option) write ] "unknown".

• Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was

• (9) acquired has, or may, become

• entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be

included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom

the relevant interest was acquired.